6-chloro-7-methyl-1H-indole | 57817-09-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 6-chloro-7-methyl-1H-indole
• CAS: 57817-09-1
• 化学式: C₉H₈ClN
• mdl: MFCD09027020
• 分子量: 165.622
• InChiKey: IUVDZGZOHOXWKG-UHFFFAOYSA-N

物化性质

• 沸点：
  299.1±20.0 °C(Predicted)
• 密度：
  1.273±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  15.8
• 氢给体数：
  1
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  6-chloro-7-methyl-1H-indole 在 O-diphenylphosphinyl hydroxylamine 、 potassium hydroxide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 6-Chloro-7-methylindol-1-amine
  参考文献：
  名称：

  对称阴离子介导的动态动力学不对称 Knoevenagel 反应用于 N−C 和 N−N 阻转异构体的合成

  摘要：

  对称阴离子介导的动态动力学不对称 Knoevenagel 反应被建立为获取 CN-N 和 N-N 阻转异构体的通用且有效的方法。所得的高对映纯吡啶-2,6(1 H ,3 H )-二酮表现出不同的结构和官能团。机理研究进一步揭示了立体化学信息如何从催化剂转移到轴向手性产物中。

  DOI：

  10.1002/anie.202410012

文献信息

• [EN] MONO- OR DI-SUBSTITUTED INDOLE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS<br/>[FR] DÉRIVÉS D'INDOLE MONOSUBSTITUÉS OU DISUBSTITUÉS UTILISÉS EN TANT QU'INHIBITEURS DE LA RÉPLICATION DU VIRUS DE LA DENGUE
  申请人：JANSSEN PHARMACEUTICALS INC

  公开号：WO2017046258A1

  公开（公告）日：2017-03-23

  The present invention concerns mono- or di-substituted indole compounds, methods to prevent or treat dengue viral infections by using said compounds and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.

  本发明涉及单取代或双取代吲哚化合物，通过使用该化合物来预防或治疗登革病毒感染的方法，还涉及该化合物用作药物，更好地用于治疗或预防登革病毒感染。本发明还涉及药物组合中的药物组成或组合制剂，用作药物的组成或制剂，更好地用于预防或治疗登革病毒感染。该发明还涉及该化合物的制备过程。
• [EN] MONO- OR DI-SUBSTITUTED INDOLES AS DENGUE VIRAL REPLICATION INHIBITORS<br/>[FR] INDOLES MONOSUBSTITUÉS OU DISUBSTITUÉS UTILISÉS EN TANT QU'INHIBITEURS DE LA RÉPLICATION DU VIRUS DE LA DENGUE
  申请人：JANSSEN PHARMACEUTICALS INC

  公开号：WO2016050831A1

  公开（公告）日：2016-04-07

  The present invention concerns mono- or di-substituted indole compounds of formula (I) which are useful to prevent or treat dengue viral infections and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.

  本发明涉及式（I）的单取代或二取代吲哚化合物，其可用于预防或治疗登革热病毒感染，并且还涉及所述化合物的药用，更好地用于治疗或预防登革热病毒感染。本发明还涉及所述化合物的制药组合物或混合制剂，涉及该组合物或制剂用作药物，更好地用于预防或治疗登革热病毒感染。本发明还涉及制备所述化合物的工艺。
• [EN] INDOLE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS<br/>[FR] DÉRIVÉS INDOLE UTILISÉS EN TANT QU'INHIBITEURS DE LA RÉPLICATION DU VIRUS DE LA DENGUE
  申请人：JANSSEN PHARMACEUTICALS INC

  公开号：WO2016113371A1

  公开（公告）日：2016-07-21

  The present invention relates to mono- or di-substituted indole compounds, methods to prevent or treat dengue viral infections by using said compounds and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.

  本发明涉及单取代或双取代吲哚化合物，通过使用这些化合物来预防或治疗登革病毒感染的方法，并且还涉及将这些化合物用作药物，更好地用作治疗或预防登革病毒感染的药物。本发明还涉及这些化合物的药用组合物或组合制剂，将这些组合物或制剂用作药物，更好地用于预防或治疗登革病毒感染。该发明还涉及这些化合物的制备方法。
• LIQUID CRYSTAL COMPOSITION
  申请人：Sumitomo Chemical Company, Limited

  公开号：US20170335191A1

  公开（公告）日：2017-11-23

  A liquid crystal composition which prevents production of an alignment defect of a liquid crystal compound and also has excellent storage stability during dissolution in a solvent is provided. The liquid crystal composition is suitable for constituting a retardation film capable of favorable circular polarization conversion. The liquid crystal composition includes a polymerizable liquid crystal compound having 3 or more ring structures in the main chain, and aluminum. A content of the aluminum is 1 ppm or more and 170 ppm or less relative to the polymerizable liquid crystal compound.

  提供了一种液晶组合物，可以防止液晶化合物的对准缺陷产生，并且在溶剂中溶解时具有优异的储存稳定性。该液晶组合物适用于构成具有良好圆偏振转换的减速膜。该液晶组合物包括具有3个或更多环结构的可聚合液晶化合物和铝。铝的含量相对于可聚合液晶化合物为1 ppm或更多，170 ppm或更少。
• Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
  申请人：Janssen Pharmaceuticals, Inc.

  公开号：US10029984B2

  公开（公告）日：2018-07-24

  The present invention relates to mono- or di-substituted indole compounds, methods to prevent or treat dengue viral infections by using said compounds and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.

  本发明涉及一取代或二取代吲哚化合物、使用所述化合物预防或治疗登革热病毒感染的方法，还涉及用作药物的所述化合物，更优选用作治疗或预防登革热病毒感染的药物。 本发明还涉及所述化合物的药物组合物或组合制剂、用作药物的组合物或制剂，更优选用作预防或治疗登革热病毒感染的药物。 本发明还涉及化合物的制备工艺。